Literature DB >> 34212237

Are all procedures for benign prostatic hyperplasia created equal? A systematic review on post-procedural PSA dynamics and its correlation with relief of bladder outlet obstruction.

Abhishek Bhat1, Ruben Blachman-Braun1, Thomas R W Herrmann2, Hemendra N Shah3.   

Abstract

PURPOSE: To evaluate and provide a comprehensive literature review of Prostate specific antigen (PSA) dynamics after various surgical procedures for benign prostatic hyperplasia (BPH).
METHODS: A thorough PubMed database search was performed over last 30 years including terms "PSA" and various surgical procedures for BPH. PSA nadir after various procedure was evaluated. The post-operative improvement in International Prostate Symptom Score, maximum void rates and post-void residue after surgeries were recorded. An indirect correlation was made between PSA nadir and outcome of various BPH surgical procedures.
RESULTS: Enucleation procedures like simple prostatectomy and endoscopic enucleation of prostate (EEP) produced maximum drop in PSA level after surgery and were associated with the highest improvement in post-operative parameters. The PSA nadir following resection techniques like transurethral resection of prostate and Holmium laser resection of prostate and vaporization technique was variable and less robust when compared to EEP. Newer techniques like Aquablation, Rezum, Urolift, Prostate artery embolization and Temporary implantable nitinol devices (iTIND) produce relatively less reduction in PSA and lesser percentile improvement in post-operative parameters.
CONCLUSIONS: Various surgical procedures for BPH result in varying PSA nadirs level. Enucleation procedures and simple prostatectomy produce the most drastic and sustained decrease in PSA. There is a possible indirect evidence suggesting that the level of PSA nadir corresponds closely with the degree of post-operative improvement and durability of the procedure. Establishing the new PSA nadir at 3-6 months after the procedure is recommended as a part of routine surveillance for prostate cancer in eligible patients.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Benign prostatic hyperplasia; Endoscopic enucleation; Laser vaporization; Photoselective vaporization; Prostate artery embolization; Prostate cancer; Prostate specific antigen; REZUM; Simple prostatectomy; TUMT; TUNA; TURP; Urolift; iTIND

Mesh:

Substances:

Year:  2021        PMID: 34212237     DOI: 10.1007/s00345-021-03771-w

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   3.661


  71 in total

1.  WATER: A Double-Blind, Randomized, Controlled Trial of Aquablation® vs Transurethral Resection of the Prostate in Benign Prostatic Hyperplasia.

Authors:  Peter Gilling; Neil Barber; Mohamed Bidair; Paul Anderson; Mark Sutton; Tev Aho; Eugene Kramolowsky; Andrew Thomas; Barrett Cowan; Ronald P Kaufman; Andrew Trainer; Andrew Arther; Gopal Badlani; Mark Plante; Mihir Desai; Leo Doumanian; Alexis E Te; Mark DeGuenther; Claus Roehrborn
Journal:  J Urol       Date:  2018-01-31       Impact factor: 7.450

2.  Serum prostate-specific antigen as a predictor of prostate volume in men with benign prostatic hyperplasia.

Authors:  C G Roehrborn; P Boyle; A L Gould; J Waldstreicher
Journal:  Urology       Date:  1999-03       Impact factor: 2.649

3.  Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia.

Authors:  L S Marks; F J Dorey; T Rhodes; E D Shery; H Rittenhouse; A W Partin; J B deKernion
Journal:  J Urol       Date:  1996-09       Impact factor: 7.450

4.  A Multicenter Randomized Noninferiority Trial Comparing GreenLight-XPS Laser Vaporization of the Prostate and Transurethral Resection of the Prostate for the Treatment of Benign Prostatic Obstruction: Two-yr Outcomes of the GOLIATH Study.

Authors:  James A Thomas; Andrea Tubaro; Neil Barber; Frank d'Ancona; Gordon Muir; Ulrich Witzsch; Marc-Oliver Grimm; Joan Benejam; Jens-Uwe Stolzenburg; Antony Riddick; Sascha Pahernik; Herman Roelink; Filip Ameye; Christian Saussine; Franck Bruyère; Wolfgang Loidl; Tim Larner; Nirjan-Kumar Gogoi; Richard Hindley; Rolf Muschter; Andrew Thorpe; Nitin Shrotri; Stuart Graham; Moritz Hamann; Kurt Miller; Martin Schostak; Carlos Capitán; Helmut Knispel; Alexander Bachmann
Journal:  Eur Urol       Date:  2015-08-15       Impact factor: 20.096

5.  Prostate specific antigen levels following transurethral resection of the prostate.

Authors:  Roberto C Fonseca; Cristiano M Gomes; Elton B Meireles; Geraldo C Freire; Miguel Srougi
Journal:  Int Braz J Urol       Date:  2008 Jan-Feb       Impact factor: 1.541

6.  Postoperative PSA and PSA velocity identify presence of prostate cancer after various surgical interventions for benign prostatic hyperplasia.

Authors:  Brian T Helfand; Christopher B Anderson; Angela Fought; Dae Y Kim; Ashish Vyas; Kevin T McVary
Journal:  Urology       Date:  2009-05-09       Impact factor: 2.649

7.  Prostate specific antigen measurements after minimally invasive surgery of the prostate in men with benign prostatic hypertrophy.

Authors:  W B Shingleton; F Terrell; J Kolski; W May; D L Renfroe; J E Fowler
Journal:  Prostate Cancer Prostatic Dis       Date:  2000-11       Impact factor: 5.554

8.  Enhanced expression of prostate-specific antigen in the transition zone of the prostate. A characterization following prostatectomy for benign hyperplasia.

Authors:  F Recker; M K Kwiatkowski; K Pettersson; T Piironen; G Lümmen; A Huber; R Tscholl
Journal:  Eur Urol       Date:  1998       Impact factor: 20.096

9.  Reference range of prostate-specific antigen after transurethral resection of the prostate.

Authors:  G Aus; S Bergdahl; R Frösing; P Lodding; E Pileblad; J Hugosson
Journal:  Urology       Date:  1996-04       Impact factor: 2.649

10.  Do patients have to choose between ejaculation and miction? A systematic review about ejaculation preservation technics for benign prostatic obstruction surgical treatment.

Authors:  Souhil Lebdai; Armand Chevrot; Steeve Doizi; Benjamin Pradere; Nicolas Barry Delongchamps; Amine Benchikh; Jean Nicolas Cornu; Emmanuel Della Negra; Marc Fourmarier; Vincent Misraï; Pierre Etienne Theveniaud; Aurélien Descazeaud; Grégoire Robert
Journal:  World J Urol       Date:  2018-07-02       Impact factor: 4.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.